Triomics, a pioneering company in cancer care, has secured $15 million in funding to advance their mission of transforming oncology workflows through the power of generative AI. Collaborating with esteemed academic cancer centers and research consortia, Triomics aims to streamline oncology processes currently burdened by manual data analysis and inefficiencies. Their solution, OncoLLM™, leverages generative AI to analyze unstructured medical data, significantly speeding up patient-trial matching and improving data extraction accuracy compared to existing methods.
Led by co-founders Sarim Khan and Hrituraj Singh, Triomics has developed OncoLLM™ to address the limitations of traditional software in handling unstructured data prevalent in oncology. Through collaborations with institutions like the Medical College of Wisconsin, Triomics has demonstrated OncoLLM™'s ability to identify eligible clinical trial patients swiftly and accurately extract data from unstructured notes. Moreover, Triomics' software suite integrates seamlessly with existing electronic health record systems, enhancing functionalities like patient-trial matching and data analysis for personalized cancer care.
Triomics' innovative approach not only accelerates oncology workflows but also holds promise in reducing provider burnout and improving patient access to critical therapies. With plans to further validate OncoLLM™'s efficacy across diverse patient populations, Triomics is poised to revolutionize cancer care with their AI-powered solutions.
Click here to read the original news story.